{"id":72180,"date":"2026-08-10T13:33:23","date_gmt":"2026-08-10T05:33:23","guid":{"rendered":"https:\/\/flcube.com\/?p=72180"},"modified":"2026-08-10T13:33:25","modified_gmt":"2026-08-10T05:33:25","slug":"recursion-and-roche-genentech-reach-first-validated-target-milestone-in-usd-12-billion-ai-drug-discovery-alliance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72180","title":{"rendered":"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Recursion<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RXRX:NASDAQ\">NASDAQ: RXRX<\/a>) and <strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>), together with its subsidiary <strong>Genentech<\/strong>, announced a milestone in their <strong>up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration<\/strong>. The companies plan to <strong>co\u2011develop a neuroscience small molecule early discovery program<\/strong> based on the <strong>first validated target<\/strong> discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.<\/p>\n\n\n\n<h2 id=\"h-milestone-overview\" class=\"wp-block-heading\">Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Recursion (NASDAQ: RXRX) + Roche Holding (SWX: ROP; OTCMKTS: RHHBY) \/ Genentech<\/td><\/tr><tr><td><strong>Collaboration Value<\/strong><\/td><td>Up to USD 12 billion<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First validated target discovered via jointly created AI map<\/td><\/tr><tr><td><strong>Trigger<\/strong><\/td><td>Genentech exercised the collaboration&#8217;s first validated target option<\/td><\/tr><tr><td><strong>Payment Triggered<\/strong><\/td><td>USD 3 million milestone payment to Recursion<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Neuroscience small molecule early discovery program<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-target-validation-amp-payment-details\" class=\"wp-block-heading\">Target Validation &amp; Payment Details<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Validation Package:<\/strong> <strong>Genentech<\/strong> exercised the collaboration&#8217;s first validated target option after accepting a <strong>validation package<\/strong> for the target from <strong>Recursion<\/strong>.<\/li>\n\n\n\n<li><strong>Milestone Payment:<\/strong> The acceptance triggered a <strong>USD 3 million milestone payment<\/strong> from the biopharma giants to Recursion.<\/li>\n\n\n\n<li><strong>Cumulative Cash:<\/strong> Since the AI\u2011based drug developer joined forces with <strong>Roche<\/strong> and <strong>Genentech<\/strong> to launch the partnership in <strong>2021<\/strong>, total cash paid out by the biopharma giants to Recursion has reached <strong>USD 216 million<\/strong>.<\/li>\n\n\n\n<li><strong>Timeline:<\/strong> Recursion said it took the companies <strong>15 months<\/strong> to go from initiation of target validation to a completed validation package.<\/li>\n\n\n\n<li><strong>Undisclosed Details:<\/strong> The companies are not disclosing what the validated target is, or what neurological disorders it has the potential to treat.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-terms-per-program\" class=\"wp-block-heading\">Commercial Terms Per Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 300 million per program (development, commercialization, and net sales milestones)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties up to high single digits per small molecule program<\/td><\/tr><tr><td><strong>Committed Programs<\/strong><\/td><td>40 programs across the platform<\/td><\/tr><tr><td><strong>Therapeutic Scope<\/strong><\/td><td>&#8220;Key areas&#8221; of neuroscience; an undisclosed gastrointestinal\u2011oncology indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Roche<\/strong> and <strong>Genentech<\/strong> have committed to using <strong>Recursion&#8217;s platform<\/strong> to advance therapies in <strong>40 programs<\/strong> that include &#8220;key areas&#8221; of neuroscience and an undisclosed gastrointestinal\u2011oncology indication.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Validation:<\/strong> The first exercised target option provides tangible evidence that Recursion&#8217;s AI mapping approach can generate targets accepted by one of the world&#8217;s largest pharmaceutical R&amp;D organizations \u2014 a closely watched proof point for AI\u2011driven drug discovery.<\/li>\n\n\n\n<li><strong>Revenue Stream:<\/strong> With USD 216 million already paid since 2021 and up to USD 300 million in additional milestones available per program, the alliance represents a durable potential revenue stream for Recursion as it balances platform investment against cash generation.<\/li>\n\n\n\n<li><strong>Neuroscience Bet:<\/strong> The focus on neuroscience \u2014 historically one of the highest\u2011failure\u2011rate areas in drug development \u2014 underscores the thesis that AI\u2011derived target discovery may unlock biology that conventional approaches have missed.<\/li>\n\n\n\n<li><strong>Pipeline Optionality:<\/strong> The commitment to 40 programs spanning neuroscience and gastrointestinal oncology gives the partnership multiple shots on goal, even with the first validated target&#8217;s identity and indications undisclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Recursion\u2013Roche\/Genentech collaboration, including co\u2011development plans, milestone payments, and program commitments. Actual results may differ due to risks including target validation outcomes, clinical results, and regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1111,403,163],"class_list":["post-72180","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-genentech","tag-recursion","tag-roche"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co\u2011develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72180\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance\" \/>\n<meta property=\"og:description\" content=\"Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co\u2011develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72180\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T05:33:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T05:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72180#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72180\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance\",\"datePublished\":\"2026-08-10T05:33:23+00:00\",\"dateModified\":\"2026-08-10T05:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72180\"},\"wordCount\":523,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Genentech\",\"Recursion\",\"Roche\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72180#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72180\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72180\",\"name\":\"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T05:33:23+00:00\",\"dateModified\":\"2026-08-10T05:33:25+00:00\",\"description\":\"Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co\u2011develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72180#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72180\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72180#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry","description":"Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co\u2011develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72180","og_locale":"en_US","og_type":"article","og_title":"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance","og_description":"Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co\u2011develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.","og_url":"https:\/\/flcube.com\/?p=72180","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T05:33:23+00:00","article_modified_time":"2026-08-10T05:33:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72180#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72180"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance","datePublished":"2026-08-10T05:33:23+00:00","dateModified":"2026-08-10T05:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72180"},"wordCount":523,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Genentech","Recursion","Roche"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72180#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72180","url":"https:\/\/flcube.com\/?p=72180","name":"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T05:33:23+00:00","dateModified":"2026-08-10T05:33:25+00:00","description":"Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up\u2011to\u2011USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co\u2011develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long\u2011challenging therapeutic area.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72180#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72180"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72180#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Recursion and Roche\u2011Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72180"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72180\/revisions"}],"predecessor-version":[{"id":72181,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72180\/revisions\/72181"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}